Profile data is unavailable for this security.
About the company
TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
- Revenue in JPY (TTM)57.25bn
- Net income in JPY5.25bn
- Incorporated1921
- Employees583.00
- LocationTorii Pharmaceutical Co LtdTorii Nihombashi Bldg.3-4-1, Nihombashi Hon-choCHUO-KU 103-8439JapanJPN
- Phone+81 332316811
- Fax+81 352037333
- Websitehttps://www.torii.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cuorips Inc | 19.39m | -657.94m | 60.07bn | 59.00 | -- | 10.30 | -- | 3,098.09 | -88.11 | -88.11 | 2.60 | 729.16 | 0.0032 | 1.15 | 10.60 | 328,610.20 | -10.89 | -- | -11.14 | -- | 44.66 | -- | -3,394.40 | -- | 35.37 | -- | 0.00 | -- | -39.65 | -- | -39.84 | -- | -- | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 63.17bn | 7.39bn | 65.89bn | 762.00 | 8.26 | 0.9645 | 6.67 | 1.04 | 260.93 | 260.93 | 2,230.35 | 2,235.47 | 0.7159 | 1.67 | 4.03 | 82,902,890.00 | 8.38 | 4.63 | 10.69 | 5.87 | 49.66 | 46.94 | 11.70 | 6.76 | 1.61 | -- | 0.1154 | 14.86 | 3.94 | 6.12 | 78.03 | 34.04 | -37.89 | 23.36 |
| Katakura Industries Co., Ltd. | 39.01bn | 2.90bn | 70.96bn | 1.04k | 22.94 | 0.8665 | 12.27 | 1.82 | 87.82 | 87.82 | 1,179.69 | 2,325.40 | 0.2783 | 2.21 | 5.10 | 37,506,730.00 | 2.19 | 2.35 | 2.82 | 3.34 | 38.25 | 37.75 | 7.87 | 8.32 | 2.71 | -- | 0.1076 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| JCR Pharmaceuticals Co Ltd | 40.21bn | 4.10bn | 84.69bn | 934.00 | 19.98 | 1.47 | 11.07 | 2.11 | 32.68 | 32.68 | 321.38 | 443.47 | 0.4022 | 0.5095 | 3.01 | 43,049,250.00 | 4.14 | 8.66 | 6.03 | 13.46 | 74.31 | 74.51 | 10.28 | 18.24 | 1.08 | 24.78 | 0.3364 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Kyorin Pharmaceutical Co Ltd | 120.10bn | 5.53bn | 97.30bn | 2.04k | 15.65 | 0.6653 | 9.82 | 0.8102 | 96.24 | 96.24 | 2,091.35 | 2,263.71 | 0.6815 | 1.31 | 2.83 | 58,813,420.00 | 3.14 | 3.05 | 4.07 | 3.79 | 42.90 | 47.11 | 4.60 | 4.76 | 1.30 | -- | 0.1372 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
| Torii Pharmaceutical Co Ltd | 57.25bn | 5.25bn | 107.28bn | 583.00 | 19.93 | 0.8694 | 18.85 | 1.87 | 186.93 | 186.93 | 2,036.86 | 4,284.47 | 0.4304 | 2.79 | 2.23 | 98,195,540.00 | 3.95 | 6.52 | 4.36 | 7.35 | 44.49 | 49.55 | 9.18 | 17.98 | 5.70 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Nxera Pharma Co Ltd | 23.34bn | -9.84bn | 113.73bn | 350.00 | -- | 1.65 | -- | 4.87 | -115.16 | -115.16 | 270.92 | 767.28 | 0.1792 | -- | 5.05 | 66,685,720.00 | -7.55 | -0.6588 | -8.18 | -0.7036 | 72.71 | 89.83 | -42.14 | -4.46 | 3.96 | -8.45 | 0.5075 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Zeria Pharmaceutical Co Ltd | 78.88bn | 9.03bn | 117.61bn | 1.78k | 10.81 | 1.19 | 7.01 | 1.49 | 204.82 | 204.82 | 1,789.40 | 1,858.72 | 0.5418 | 1.50 | 3.71 | 44,387,400.00 | 6.20 | 3.89 | 9.82 | 6.28 | 73.22 | 71.93 | 11.44 | 7.57 | 0.8393 | -- | 0.3508 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Mochida Pharmaceutical Co Ltd | 103.55bn | 4.41bn | 120.65bn | 1.52k | 25.98 | 0.896 | 16.56 | 1.17 | 123.93 | 123.93 | 2,908.72 | 3,593.56 | 0.6565 | 1.75 | 3.42 | 68,032,190.00 | 2.80 | 4.37 | 3.34 | 5.31 | 50.05 | 52.47 | 4.26 | 6.71 | 3.31 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Towa Pharmaceutical Co Ltd | 235.95bn | 16.92bn | 150.79bn | 4.59k | 8.52 | 0.8839 | 4.27 | 0.6391 | 343.72 | 343.72 | 4,793.82 | 3,311.49 | 0.5582 | 1.49 | 3.60 | 51,428,070.00 | 4.00 | 4.21 | 4.91 | 5.63 | 35.90 | 39.23 | 7.17 | 7.23 | 1.62 | -- | 0.5666 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Data as of Sep 18 2024. Currency figures normalised to Torii Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
11.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Effissimo Capital Management Pte Ltd.as of 08 Mar 2024 | 588.20k | 2.04% |
| Amundi Japan Ltd.as of 11 Sep 2024 | 491.30k | 1.71% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 417.50k | 1.45% |
| Zennor Asset Management LLPas of 31 May 2024 | 416.60k | 1.45% |
| Nomura Asset Management Co., Ltd.as of 30 Aug 2024 | 328.80k | 1.14% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 291.80k | 1.01% |
| Nikko Asset Management Co., Ltd.as of 06 Sep 2024 | 261.40k | 0.91% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 212.41k | 0.74% |
| Daiwa Asset Management Co. Ltd.as of 30 Aug 2024 | 149.40k | 0.52% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 135.00k | 0.47% |
More ▼
Data from 31 May 2024 - 05 Sep 2024Source: FactSet Research Systems Inc.
